Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA   US04033A1007

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/27/2014 10/28/2014 10/29/2014 10/30/2014 10/31/2014 Date
5.74(c) 5.97(c) 5.87(c) 5.97(c) 5.96(c) Last
3 974 031 5 945 437 3 736 471 3 552 774 5 233 591 Volume
-1.54% +4.01% -1.68% +1.70% -0.17% Change
More quotes
Company
ARIAD Pharmaceuticals, Inc. operates as a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer.The company has four products: Ridaforolimus, Ponatinib, AP1903 and AP26113.Its approach to structure-based drug... 
Sector
Pharmaceuticals
Calendar
11/05Earnings Release
Surperformance© rating of Ariad Pharmaceuticals, Inc
Trading Rating : Investor Rating :
More about the company
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 61,4 M
EBIT 2014 -215 M
Net income 2014 -215 M
Finance 2014 92,5 M
Yield 2014 -
Sales 2015 159 M
EBIT 2015 -140 M
Net income 2015 -135 M
Finance 2015 97,7 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 16,6x
EV / Sales 2015 6,41x
Capitalization 1 115 M
More Financials
Latest news on ARIAD PHARMACEUTICALS, INC
3d ago ARIAD PHARMACEUTICALS : Updates on Adoption of Final Opinion for Iclusig
10/24 ARIAD PHARMACEUTICALS : Other Events (form 8-K)
10/24 ARIAD PHARMACEUTICALS : Announces Adoption of Final Opinion for Iclusig by Commi..
10/22 ARIAD PHARMACEUTICALS : Announces Recommendation for Iclusig by the Pharmacovigi..
10/15 ARIAD PHARMACEUTICALS : and Bellicum Announce Revised License Agreement for 's C..
10/15 ARIAD PHARMACEUTICALS : to Webcast Conference Call on Third Quarter 2014 Financi..
10/10 ARIAD PHARMACEUTICALS : Announces Recommendation for Iclusig by the Pharmacovigi..
10/10 ARIAD PHARMACEUTICALS : Entry into a Material Definitive Agreement, Financial St..
10/08 ARIAD PHARMACEUTICALS : AP26113 Receives FDA Breakthrough Therapy Designation Fo..
10/08 ARIAD PHARMACEUTICALS : Presents Updated Clinical Data on AP26113 in Patients wi..
10/06 ARIAD PHARMACEUTICALS : and Bellicum Announce Revised License Agreement for &rsq..
10/02 ARIAD PHARMACEUTICALS : AP26113 Receives FDA Breakthrough Therapy Designation Fo..
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF